inmunotek
alergia e inmunología

ALXOID®

More info:
www.inmunotek.com

ALXOID®: **rapid** and **convenient immunotherapy schedule**

EFFICACY

Subcutaneous immunotherapy with polymerized extract proved to be **significantly efficacious**[2,3]

MEAN SYMPTOM SCORE WAS REDUCED DURING THE PEAK POLLEN SEASON[3]

Multicentre, prospective, randomised, double-blind, placebo-controlled study evaluating the efficacy, safety and tolerability of subcutaneous immunotherapy with a mixture of highly polymerised grass and rye pollens, in a cluster schedule, in patients with allergic rhinoconjunctivitis with or without controlled asthma (N=121)

Figure taken from Klimek L, et al.[3]



IN LESS THAN 2.5 MONTHS[2]

the majority of patients needed significant greater threshold concentrations for a positive specific Nasal Provocation Test at the end of the study (p=0.002)

Prospective, randomised, controlled, open-label study evaluating the efficacy of subcutaneous immunotherapy with a mixture of polymerized grass pollens, in a cluster schedule, in patients with allergic rhinitis with or without asthma (N=33)

SAFETY

Subcutaneous immunotherapy with polymerized extract was **safe**[4]

Even at **higher doses and in mixtures** of unrelated allergen **extracts**[4]

With **fewer adverse reactions** than reported with **native** allergen **extracts**[4]

With **no significant differences** between **children and adults**[4]

Observational, multicentre study evaluating the safety of subcutaneous immunotherapy, at different concentrations and mixtures, in paediatric and adult patients with or without asthma (N=1855)

Maintenance dose

Vial A and B

CONVENTIONAL SCHEDULE
Maintenance dose in 3 weeks

BUILD-UP

Day 0	Day 7	Day 14	Day 21
0.2 mL (Vial A)	0.5 mL (Vial A)	0.2 mL (Vial B)	0.5 mL (Vial B)
Every 7 days			

MAINTENANCE

0.5 mL — Every 30 days

VIAL A: 2,000 TU/mL. Extractable volume: 2.5 mL
VIAL B: 10,000 TU/mL. Extractable volume: 2.5 mL
Approximate duration of maintenance treatment (Vial B): 5 months

Vial B

CONVENTIONAL SCHEDULE
Maintenance dose in 1 week

BUILD-UP

Day 0	Day 7
0.2 mL	0.5 mL

MAINTENANCE

0.5 mL — Every 30 days

Extractable volume: 2.5 mL
Approximate duration of maintenance treatment (1 vial): 5 months

RUSH SCHEDULE
Maintenance dose on 1st day

BUILD-UP

Day 0	30 min	Day 0
0.2 mL		0.3 mL

MAINTENANCE

0.5 mL — Every 30 days

Extractable volume: 2.5 mL
Approximate duration of maintenance treatment (1 vial): 5 months

Wide catalogue of allergens



ALXOID® Vial A

2,000 TU/mL



ALXOID® Vial B

10,000 TU/mL

ALXOID®

POLLEN
6 Grasses[1]
2 Grasses[2]
Cynodon dactylon
Lolium perenne
Olea europaea
Cupressaceae
Platanus hispanica
Artemisia vulgaris
Chenopodium album
Parietaria judaica
Salsola kali
DUST MITES
Dermatophagoides (D. pteronyssinus, D. farinae)
D. pteronyssinus
D. farinae
Lepidoglyphus destructor
Tyrophagus putrescentiae
Blomia tropicalis
DANDER
Cat
Dog

TU: Therapeutic Units
1. Dactylis glomerata, Poa pratensis, Holcus lanatus, Festuca elatior, Phleum pratense, Lolium perenne. 2. Dactylis glomerata, Trisetum paniceum.

ALXOID®

ALXOID® is a subcutaneous immunotherapy product.

Composition: the active substances are one or several standardised polymerized allergen extracts (2,000 TU*/mL Vial A; 10,000 TU/mL Vial B)**.

Excipients: aluminium hydroxide gel, sodium chloride, phenol and water for injection.

Pharmaceutical form: suspension for injection.

***Presentations:* ALXOID®** has the following presentations:

- Initiation treatment: 1 Vial A and 1 or 2 Vials B.
- Maintenance treatment: 1 or 2 Vials B.

All vials are packed in sterile clear glass vials, closed with butyl-rubber stoppers and secured with an aluminium cap.

Therapeutic indications: ALXOID® is indicated for adults and children to treat type I allergic diseases (IgE-mediated), such as rhinitis/rhinoconjunctivitis and bronchial asthma.

Method of administration: It must be administered subcutaneously in health centers under medical supervision.

The initiation treatment with **ALXOID®** begins with the vial of the lowest concentration (Vial A):

- Day 1: 0.2 mL
- Day 7: 0.5 mL

Once the 0.5 mL dose of Vial A is reached, continue the following week with the vial B.

- Day 14: 0.2 mL
- Day 21: 0.5 mL

In case a Vial A is not ordered, start directly with Vial B, as established by your doctor: Conventional regime (maintenance dose reached within 1 week) or Rush regimen (maintenance is reached the first day, administering two doses in alternate arms, 0.2 mL and 0.3 mL, separated by 30 minutes) The maintenance treatment with **ALXOID®** consists of the administration a 0.5 mL (vial B) dose, monthly.

Storage: store in a refrigerator (2–8°C). Do not freeze. Keep out of sight and reach of children.

Revised: July 2021

*TU: Therapeutic Units.

**allergen: Mixture of *Dermatophagoides (Dermatophagoides pteronyssinus + Dermatophagoides farinae)* and grass mixture *(Dactylis glomerata + Trisetum peniceum, Dactylis glomerata + Poa pratensis + Holcus lanatus + Festuca elatior + Phleum pratense + Lolium perenne)* is considered as a single allergen.

TU: Therapeutic Units.

1. ALXOID® summary of product characteristics.
2. Subiza J, et al. Cluster immunotherapy with a glutaraldehyde-modified mixture of grasses results in an improvement in specific nasal provocation tests in less than 2.5 months of treatment. Clinical and Experimental Allergy 2008; 38(6):987-994.
3. Klimek L, et al. A high polymerized grass pollen extract is efficacious and safe in a randomised double-blind, placebo-controlled study using a novel up-dosing cluster-protocol. Allergy 2014; 69: 1629-1638.
4. Guzman-Fulgencio M, et al. Safety of immunotherapy with glutaraldehyde modifiedallergen extracts in children and adults. Allergol Immunopathol 2017:45(2):198-207

ALX-IBO-23000001 (January 2023)

inmunotek
alergia e inmunología

نمایندگی انحصاری در ایران
شرکت سامان دارو سلامت

Punto Mobi, 5 | Parque Científico Tecnológico
28805 Alcalá de Henares | Madrid, Spain | Tel.: 912 908 942

www.inmunotek.com www.samanpharma.com